9 results on '"Sheng, Hui"'
Search Results
2. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer
- Author
-
Xiao-dong Chu, Zheng-bin Lin, Ting Huang, Hui Ding, Yi-ran Zhang, Zhan Zhao, Shu-chen Huangfu, Sheng-hui Qiu, Yan-guan Guo, Xiao-li Chu, Jing-hua Pan, and Yun-long Pan
- Subjects
Gastric cancer ,Thrombospondin 2 ,Clinical characteristics ,Prognosis ,Lymphatic metastasis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background This study aims to investigate thrombospondin 2 (TSP2) expression levels in gastric cancer (GC) and determine the relationship between TSP2 and clinical characteristics and prognosis. Methods The online database Gene Expression Profile Interactive Analysis (GEPIA) was used to analyse TSP2 mRNA expression levels in GC. The Kaplan–Meier plotter prognostic analysis tool was used to evaluate the influence of TSP2 expression on clinical prognosis in GC patients. TSP2 expression levels were analysed in paraffin-embedded GC samples and adjacent normal tissues by immunohistochemistry. The relationship between the clinicopathological characteristics and prognosis of GC patients was assessed. Transwell experiments were used to evaluate the effect of TSP2 on HGC27 and AGS cell invasion and migration. The EdU experiment was used to detect the effect of transfection of TSP2 on cell proliferation, and the flow cytometry experiment was used to detect the effect of TSP2 on cell apoptosis and the cell growth cycle. Western blotting (Wb) technology was used to detect MMP, E-cadherin, N-cadherin, Vimentin, Snail, AKT, PI3K, and VEGF protein expression in HGC27 cells. Results Compared with normal tissues, TSP2 mRNA expression in GC was significantly upregulated and was closely related to the clinical stage of GC. High TSP2 expression significantly affected the OS, FP and PPS of patients with GC. Among these patients, TSP2 expression levels did not affect the prognosis of patients with GC in the N0 subgroup but significantly affected the prognosis of patients with GC in the N (1 + 2 + 3) subgroup. TSP2 protein expression levels were significantly higher in GC tissue compared with normal tissues (P
- Published
- 2022
- Full Text
- View/download PDF
3. Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer
- Author
-
Sheng, Hui, Wei, Xiaoli, Mao, Minjie, He, Jincan, Luo, Tianqi, Lu, Shilin, Zhou, Liye, Huang, Zhixin, and Yang, Anli
- Published
- 2019
- Full Text
- View/download PDF
4. Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
- Author
-
Yu-Ting Kao, Chin-Han Wu, Shan-Ying Wu, Sheng-Hui Lan, Hsiao-Sheng Liu, and Ya-Shih Tseng
- Subjects
Aurora-A ,Arsenic ,Bladder ,Carcinogenesis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Arsenic is a widely distributed metalloid compound that has biphasic effects on cultured cells. In large doses, arsenic can be toxic enough to trigger cell death. In smaller amounts, non-toxic doses may promote cell proliferation and induces carcinogenesis. Aberration of chromosome is frequently detected in epithelial cells and lymphocytes of individuals from arsenic contaminated areas. Overexpression of Aurora-A, a mitotic kinase, results in chromosomal instability and cell transformation. We have reported that low concentration (≦1 μM) of arsenic treatment increases Aurora-A expression in immortalized bladder urothelial E7 cells. However, how arsenic induces carcinogenesis through Aurora-A activation remaining unclear. Methods Bromodeoxyuridine (BrdU) staining, MTT assay, and flow cytometry assay were conducted to determine cell proliferation. Messenger RNA and protein expression levels of Aurora-A were detected by reverse transcriptional-PCR and Western blotting, respectively. Centrosome of cells was observed by immunofluorescent staining. The transcription factor of Aurora-A was investigated by promoter activity, chromosome immunoprecipitation (ChIP), and small interfering RNA (shRNA) assays. Mouse model was utilized to confirm the relationship between arsenic and Aurora-A. Results We reveal that low dosage of arsenic treatment increased cell proliferation is associated with accumulated cell population at S phase. We also detected increased Aurora-A expression at mRNA and protein levels in immortalized bladder urothelial E7 cells exposed to low doses of arsenic. Arsenic-treated cells displayed increased multiple centrosome which is resulted from overexpressed Aurora-A. Furthermore, the transcription factor, E2F1, is responsible for Aurora-A overexpression after arsenic treatment. We further disclosed that Aurora-A expression and cell proliferation were increased in bladder and uterus tissues of the BALB/c mice after long-term arsenic (1 mg/L) exposure for 2 months. Conclusion We reveal that low dose of arsenic induced cell proliferation is through Aurora-A overexpression, which is transcriptionally regulated by E2F1 both in vitro and in vivo. Our findings disclose a new possibility that arsenic at low concentration activates Aurora-A to induce carcinogenesis.
- Published
- 2017
- Full Text
- View/download PDF
5. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
- Author
-
Mao, Minjie, primary, Wang, Xueping, additional, Sheng, Hui, additional, Liu, Yijun, additional, Zhang, Lin, additional, Dai, Shuqin, additional, and Chi, Pei-dong, additional
- Published
- 2018
- Full Text
- View/download PDF
6. Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
- Author
-
Ya Shih Tseng, Shan Ying Wu, Yu Ting Kao, Sheng Hui Lan, Hsiao Sheng Liu, and Chin Han Wu
- Subjects
0301 basic medicine ,Cancer Research ,Small interfering RNA ,Programmed cell death ,Chromatin Immunoprecipitation ,Carcinogenesis ,Bladder ,Cell ,Blotting, Western ,chemistry.chemical_element ,Fluorescent Antibody Technique ,Biology ,medicine.disease_cause ,lcsh:RC254-282 ,Aurora-A ,Arsenic ,Small hairpin RNA ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Humans ,MTT assay ,Aurora Kinase A ,Cell Proliferation ,Carcinoma, Transitional Cell ,Mice, Inbred BALB C ,Cell growth ,Reverse Transcriptase Polymerase Chain Reaction ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Flow Cytometry ,Molecular biology ,Immunohistochemistry ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,chemistry ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,biological phenomena, cell phenomena, and immunity ,E2F1 Transcription Factor ,Research Article - Abstract
Background Arsenic is a widely distributed metalloid compound that has biphasic effects on cultured cells. In large doses, arsenic can be toxic enough to trigger cell death. In smaller amounts, non-toxic doses may promote cell proliferation and induces carcinogenesis. Aberration of chromosome is frequently detected in epithelial cells and lymphocytes of individuals from arsenic contaminated areas. Overexpression of Aurora-A, a mitotic kinase, results in chromosomal instability and cell transformation. We have reported that low concentration (≦1 μM) of arsenic treatment increases Aurora-A expression in immortalized bladder urothelial E7 cells. However, how arsenic induces carcinogenesis through Aurora-A activation remaining unclear. Methods Bromodeoxyuridine (BrdU) staining, MTT assay, and flow cytometry assay were conducted to determine cell proliferation. Messenger RNA and protein expression levels of Aurora-A were detected by reverse transcriptional-PCR and Western blotting, respectively. Centrosome of cells was observed by immunofluorescent staining. The transcription factor of Aurora-A was investigated by promoter activity, chromosome immunoprecipitation (ChIP), and small interfering RNA (shRNA) assays. Mouse model was utilized to confirm the relationship between arsenic and Aurora-A. Results We reveal that low dosage of arsenic treatment increased cell proliferation is associated with accumulated cell population at S phase. We also detected increased Aurora-A expression at mRNA and protein levels in immortalized bladder urothelial E7 cells exposed to low doses of arsenic. Arsenic-treated cells displayed increased multiple centrosome which is resulted from overexpressed Aurora-A. Furthermore, the transcription factor, E2F1, is responsible for Aurora-A overexpression after arsenic treatment. We further disclosed that Aurora-A expression and cell proliferation were increased in bladder and uterus tissues of the BALB/c mice after long-term arsenic (1 mg/L) exposure for 2 months. Conclusion We reveal that low dose of arsenic induced cell proliferation is through Aurora-A overexpression, which is transcriptionally regulated by E2F1 both in vitro and in vivo. Our findings disclose a new possibility that arsenic at low concentration activates Aurora-A to induce carcinogenesis.
- Published
- 2016
7. Arsenic treatment increase Aurora-A overexpression through E2F1 activation in bladder cells
- Author
-
Kao, Yu-Ting, primary, Wu, Chin-Han, additional, Wu, Shan-Ying, additional, Lan, Sheng-Hui, additional, Liu, Hsiao-Sheng, additional, and Tseng, Ya-Shih, additional
- Published
- 2017
- Full Text
- View/download PDF
8. Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity
- Author
-
Yeh, Hsuan-Heng, primary, Tseng, Yu-Fen, additional, Hsu, Yu-Chiao, additional, Lan, Sheng-Hui, additional, Wu, Shan-Ying, additional, Raghavaraju, Giri, additional, Cheng, Da-En, additional, Lee, Ying-Ray, additional, Chang, Tsuey-Yu, additional, Chow, Nan-Haw, additional, Hung, Wen-Chun, additional, and Liu, Hsiao-Sheng, additional
- Published
- 2015
- Full Text
- View/download PDF
9. Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity.
- Author
-
Hsuan-Heng Yeh, Yu-Fen Tseng, Yu-Chiao Hsu, Sheng-Hui Lan, Shan-Ying Wu, Giri Raghavaraju, Da-En Cheng, Ying-Ray Lee, Tsuey-Yu Chang, Nan-Haw Chow, Wen-Chun Hung, and Hsiao-Sheng Liu
- Subjects
LUNG cancer diagnosis ,METASTASIS ,GENETIC regulation ,NEOPLASTIC cell transformation ,GENETIC mutation ,RETINOBLASTOMA protein ,PROMOTERS (Genetics) - Abstract
Background: Mutant Ras plays multiple functions in tumorigenesis including tumor formation and metastasis. Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a metastasis inhibitor gene, suppresses matrix metalloproteinase (MMP) activity in the metastatic cascade. Clarifying the relationship between Ras and RECK and understanding the underlying molecular mechanism may lead to the development of better treatment for Ras-related tumors. Methods: Suppression subtractive hybridization PCR (SSH PCR) was conducted to identify Ha-ras
val12 up-regulated genes in bladder cancer cells. Stable cell lines of human breast cancer (MCF-7-ras) and mouse NIH3T3 fibroblasts (7-4) harboring the inducible Ha-rasval12 oncogene, which could be induced by isopropylthio-β-D-galactoside (IPTG), were used to clarify the relationship between Ras and the up-regulated genes. Chromatin immunoprecipitation (ChIP) assay, DNA affinity precipitation assay (DAPA) and RECK reporter gene assay were utilized to confirm the complex formation and binding with promoters. Results: Retinoblastoma binding protein-7 (RbAp46) was identified and confirmed as a Ha-rasval12 up-regulated gene. RbAp46 could bind with histone deacetylase (HDAC1) and Sp1, followed by binding to RECK promoter at the Sp1 site resulting in repression of RECK expression. High expression of Ras protein accompanied with high RbAp46 and low RECK expression were detected in 75% (3/4) of the clinical bladder cancer tumor tissues compared to the adjacent normal parts. Ras induced RbAp46 expression increases invasion of the bladder cancer T24 cells and MMP-9 activity was increased, which was confirmed by specific lentiviral shRNAs inhibitors against Ras and RbAp46. Similarly, knockdown of RbAp46 expression in the stable NIH3T3 cells "7-4" by shRNA decreased Ras-related lung metastasis using a xenograft nude mice model. Conclusions: We confirmed that RbAp46 is a Ha-rasval12 up-regulated gene and binds with HDAC1 and Sp1. Furthermore, RbAp46 binds to the RECK promoter at the Sp1 site via recruitment by Sp1. RECK is subsequently activated, leading to increased MMP9 activity, which may lead to increased metastasis in vivo. Our findings of Ras upregulation of RbAp46 may lead to revealing a novel mechanism of Ras-related tumor cell metastasis. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.